Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other financing activities (2018 - 2022)

Historic Other financing activities for Zevra Therapeutics (ZVRA) over the last 6 years, with Q4 2022 value amounting to -$68000.0.

  • Zevra Therapeutics' Other financing activities changed N/A to -$68000.0 in Q4 2022 from the same period last year, while for Sep 2024 it was -$68000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.1 million for FY2024, which is N/A changed from last year.
  • Per Zevra Therapeutics' latest filing, its Other financing activities stood at -$68000.0 for Q4 2022.
  • Over the past 5 years, Zevra Therapeutics' Other financing activities peaked at $2.9 million during Q1 2021, and registered a low of -$68000.0 during Q4 2022.
  • For the 4-year period, Zevra Therapeutics' Other financing activities averaged around $444142.9, with its median value being $63000.0 (2020).
  • In the last 5 years, Zevra Therapeutics' Other financing activities surged by 837352.94% in 2021 and then crashed by 9763.97% in 2022.
  • Quarter analysis of 4 years shows Zevra Therapeutics' Other financing activities stood at $144000.0 in 2018, then crashed by 109.03% to -$13000.0 in 2020, then surged by 22261.54% to $2.9 million in 2021, then plummeted by 102.36% to -$68000.0 in 2022.
  • Its Other financing activities was -$68000.0 in Q4 2022, compared to $68000.0 in Q1 2022 and $2.9 million in Q1 2021.